Sinovac BiotechSVA
About: Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Employees: 3,261
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 26 [Q1] → 26 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.24% less ownership
Funds ownership: 23.94% [Q1] → 23.7% (-0.24%) [Q2]
0% less capital invested
Capital invested by funds: $421M [Q1] → $420M (-$1.19M) [Q2]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SVA.